Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).

Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.

Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.